Ron Leuty of the San Francisco Business Times featured 23-year old Laura Deming's Longevity Fund and its new accelerator, Age1, through which Deming hopes to create an ecosystem of companies working towards treatments for aging-related diseases.
Deming, a founding partner at Longevity Fund, started working in a lab at UCSF at age 12, helping to extend the lifespan of a type of worm through genetic engineering. She was accepted to MIT at age 14 to work on artificial organogenesis and bone aging. She dropped out her sophomore year to accept a $100,000 grant from the Thiel Fellowship, and Longevity Fund was born.
"There's really not a great community of aging and longevity founders right now," said Deming, who has raised $27 million for San Francisco-based Longevity Fund in two funds. "I'm excited about the ability for us to help them."